Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Bladder Cancer
Join Thomas W. Flaig, MD and Shandra Wilson, MD from University of Colorado Cancer Center as they present their expertise on a range of cases pertaining to bladder cancer.
Bladder cancer is the most common urological cancer. An estimated 76,960 new cases of urinary bladder cancer were diagnosed in the United States in 2016, with approximately 16,390 deaths occurring during this same period. The spectrum of bladder cancer includes non-muscle-invasive, muscle-invasive, and metastatic disease, and treatment of urothelial bladder cancer is influenced by the stage and grade of the cancer. Multimodality approaches and immunotherapies are demonstrating improved outcomes for patients with urothelial carcinomas. However, in order to effectively integrate these therapies into practice, clinician awareness of the importance of patient selection and subsequent monitoring for adverse events is essential.
This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.
Thomas W. Flaig, MD
University of Colorado Cancer Center
Shandra Wilson, MD
University of Colorado Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity code: I00028181; Approval Number: 170003189
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-079-L01-P
- 1.00 CCM clock hours
- 1.00 ACPE contact hours
- 1.00 ANCC contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Following this activity, participants should be able to:
- Review the treatment options for patients with bladder cancer and how they relate to tumor stage and grade.
- Describe potential similarities and differences among emerging immunotherapies for urothelial carcinoma.
- Discuss the types of adverse events associated with traditional oncology treatment modalities and immunotherapy in patients with urothelial carcinoma.